GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (MEX:VRTX) » Definitions » Piotroski F-Score

Vertex Pharmaceuticals (MEX:VRTX) Piotroski F-Score : 0 (As of Dec. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Vertex Pharmaceuticals Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vertex Pharmaceuticals has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Vertex Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of Vertex Pharmaceuticals was 9. The lowest was 0. And the median was 6.


Vertex Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Vertex Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Piotroski F-Score Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 6.00 7.00 3.00

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 1.00 -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 16444.651 + 18249.242 + -65835.122 + 20584.24 = MXN-10,557 Mil.
Cash Flow from Operations was 3982.159 + 21684.667 + -68766.339 + 26971.773 = MXN-16,128 Mil.
Revenue was 42736.064 + 44653.884 + 48467.665 + 54579.543 = MXN190,437 Mil.
Gross Profit was 36489.541 + 38968.007 + 41654.418 + 46849.131 = MXN163,961 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(378446.44 + 385828.052 + 396939.27 + 368822.146 + 437916.21) / 5 = MXN393590.4236 Mil.
Total Assets at the begining of this year (Sep23) was MXN378,446 Mil.
Long-Term Debt & Capital Lease Obligation was MXN33,531 Mil.
Total Current Assets was MXN193,046 Mil.
Total Current Liabilities was MXN78,232 Mil.
Net Income was 15965.274 + 12613.895 + 15698.669 + 18033.784 = MXN62,312 Mil.

Revenue was 44893.439 + 42805.77 + 42743.172 + 43259.831 = MXN173,702 Mil.
Gross Profit was 39370.222 + 37994.897 + 37452.564 + 37708.428 = MXN152,526 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(336049.236 + 353869.947 + 342009.955 + 348864.65 + 378446.44) / 5 = MXN351848.0456 Mil.
Total Assets at the begining of last year (Sep22) was MXN336,049 Mil.
Long-Term Debt & Capital Lease Obligation was MXN12,972 Mil.
Total Current Assets was MXN255,985 Mil.
Total Current Liabilities was MXN62,698 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vertex Pharmaceuticals's current Net Income (TTM) was -10,557. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vertex Pharmaceuticals's current Cash Flow from Operations (TTM) was -16,128. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-10556.989/378446.44
=-0.0278956

ROA (Last Year)=Net Income/Total Assets (Sep22)
=62311.622/336049.236
=0.18542408

Vertex Pharmaceuticals's return on assets of this year was -0.0278956. Vertex Pharmaceuticals's return on assets of last year was 0.18542408. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Vertex Pharmaceuticals's current Net Income (TTM) was -10,557. Vertex Pharmaceuticals's current Cash Flow from Operations (TTM) was -16,128. ==> -16,128 <= -10,557 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=33530.612/393590.4236
=0.08519164

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=12971.853/351848.0456
=0.03686777

Vertex Pharmaceuticals's gearing of this year was 0.08519164. Vertex Pharmaceuticals's gearing of last year was 0.03686777. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=193045.67/78231.531
=2.46761974

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=255984.627/62697.578
=4.08284714

Vertex Pharmaceuticals's current ratio of this year was 2.46761974. Vertex Pharmaceuticals's current ratio of last year was 4.08284714. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Vertex Pharmaceuticals's number of shares in issue this year was 261. Vertex Pharmaceuticals's number of shares in issue last year was 260.6. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=163961.097/190437.156
=0.8609722

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=152526.111/173702.212
=0.87808963

Vertex Pharmaceuticals's gross margin of this year was 0.8609722. Vertex Pharmaceuticals's gross margin of last year was 0.87808963. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=190437.156/378446.44
=0.50320768

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=173702.212/336049.236
=0.51689513

Vertex Pharmaceuticals's asset turnover of this year was 0.50320768. Vertex Pharmaceuticals's asset turnover of last year was 0.51689513. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+0+0+0
=0

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vertex Pharmaceuticals has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

Vertex Pharmaceuticals  (MEX:VRTX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Vertex Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines